Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

tuxobertinib (BDTX-189)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Black Diamond Therap

Drug class:

EGFR inhibitor, HER2 inhibitor

Related drugs:

‹

SYSA1901 (pertuzumab biosimilar) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

cetuximab (347)

osimertinib (301)

erlotinib (235)

gefitinib (194)

panitumumab (123)

lapatinib (107)

neratinib (102)

brigatinib (50)

aumolertinib (39)

amivantamab-vmjw (25)

firmonertinib (14)

mobocertinib (12)

lazertinib (12)

tarloxotinib bromide (7)

nimotuzumab (6)

rociletinib (5)

tomuzotuximab (4)

necitumumab (3)

befotertinib (3)

sunvozertinib (3)

zorifertinib (3)

ABP 494 (cetuximab biosimilar) (1)

Compound 6a (1)

abivertinib (1)

sevabertinib (1)

STI-001 (cetuximab biosimilar) (0)

antroquinonol (0)

zalutumumab (0)

JNJ-26483327 (0)

asandeutertinib (0)

PF-08046052 (0)

rindopepimut (0)

Undisclosed EGFR inhibitor (0)

cetuximab biosimilar (0)

PF-06747775 (0)

JNJ-64041757 (0)

trastuzumab (407)

trastuzumab-pkrb (24)

margetuximab-cmkb (18)

poziotinib (17)

zenocutuzumab-zbco (16)

trastuzumab-dttb (11)

zanidatamab-hrii (11)

trastuzumab-strf (9)

trastuzumab-anns (9)

trastuzumab-dkst (9)

trastuzumab-qyyp (9)

Undisclosed allogeneic Vγ9Vδ2 HER2-TAC T (4)

pertuzumab/trastuzumab/hyaluronidase-zzxf (3)

trastuzumab/hyaluronidase-oysk (2)

JBJ-08–178–01 (2)

Hercease (trastuzumab biosimilar) (1)

HERtiCAD (trastuzumab biosimilar) (1)

Hervelous (trastuzumab biosimilar) (1)

EG12014 (trastuzumab biosimilar) (1)

TX05 (trastuzumab biosimilar) (1)

ALT02 (trastuzumab biosimilar) (0)

trastuzumab biosimilar (AP062) (0)

DA 3111 (trastuzumab biosimilar) (0)

HER-2/neu peptide vaccine (0)

HER2 t-haNK (0)

Hervycta (trastuzumab biosimilar) (0)

diznalimgene lisbac (0)

MVA-BN-HER2 (0)

NeuCeptin (trastuzumab biosimilar) (0)

nelipepimut-S (0)

lapuleucel-T (0)

pertuzumab-dpzb (0)

ertumaxomab (0)

trastuzumab biosimilar (SIBP-01) (0)

TAC100-HER2 (0)

glycooptimized trastuzumab-GEX (0)

TrastuRel (trastuzumab biosimilar) (0)

Undisclosed HER2Bi-armed ATC (0)

trastuzumab biosimilar (0)

trastuzumab biosimilar (0)

›

HER-2 mutation	Solid Tumor	HER-2 mutation	Solid Tumor	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B
EGFR mutation	Solid Tumor	EGFR mutation	Solid Tumor	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B
HER-2 exon 20 insertion	Solid Tumor	HER-2 exon 20 insertion	Solid Tumor	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B	BDTX-189 Sensitive: B - Late Trials BDTX-189 Sensitive : B
EGFR exon 20 insertion	Solid Tumor	EGFR exon 20 insertion	Solid Tumor	BDTX-189 Sensitive: C2 – Inclusion Criteria BDTX-189 Sensitive : C2	BDTX-189 Sensitive: C2 – Inclusion Criteria BDTX-189 Sensitive : C2
HER-2 S310F	Solid Tumor	HER-2 S310F	Solid Tumor	BDTX-189 Sensitive: C2 – Inclusion Criteria BDTX-189 Sensitive : C2	BDTX-189 Sensitive: C2 – Inclusion Criteria BDTX-189 Sensitive : C2